Citations

Clear

3942 citation(s) found for "To, Van".

Voxel size dependency, reproducibility and sensitivity of an in vivo bone loading estimation algorithm
Christen, Patrik , Schulte, Friederike A. , Zwahlen, Alexander , Boutroy, Stéphanie , Melton, L. Joseph, Amin, Shreyasee , Khosla, Sundeep , Goldhahn, Jörg , Rietbergen, Bert van , Müller, Ralph , Khosla, Sundeep

Mayo Clinic

Journal of The Royal Society Interface | January 20, 2016 | Volume: 13 | Issue: 114 | Pages: 20150991

10.1098/rsif.2015.0991 | PMID 26790999 Get It

A bone loading estimation algorithm was previously developed that provides in vivo loading conditions required for in vivo bone remodelling simulations. The algorithm derives a bone's loading history from its microstructure as assessed by high-resolution (HR) computed tomography (CT). This reverse engineering approach showed accurate and realistic results based on micro-CT and HR-peripheral quantitative CT images. However, its voxel size dependency, reproducibility and sensitivity still need to be investigated, which is the purpose of this study. Voxel size dependency was tested on cadaveric distal radii with micro-CT images scanned at 25 µm and downscaled to 50, 61, 75, 82, 100, 125 and 150 µm. Reproducibility was calculated with repeated in vitro as well as in vivo HR-pQCT measurements at 82 µm. Sensitivity was defined using HR-pQCT images from women with fracture versus non-fracture, and low versus high bone volume fraction, expecting similar and different loading histories, respectively. Our results indicate that the algorithm is voxel size independent within an average (maximum) error of 8.2% (32.9%) at 61 µm, but that the dependency increases considerably at voxel sizes bigger than 82 µm. In vitro and in vivo reproducibility are up to 4.5% and 10.2%, respectively, which is comparable to other in vitro studies and slightly higher than in other in vivo studies. Subjects with different bone volume fraction were clearly distinguished but not subjects with and without fracture. This is in agreement with bone adapting to customary loading but not to fall loads. We conclude that the in vivo bone loading estimation algorithm provides reproducible, sensitive and fairly voxel size independent results at up to 82 µm, but that smaller voxel sizes would be advantageous.
Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer
Winham, Stacey J. , Pirie, Ailith, Chen, Y. Ann , Fogarty, Zachary C. , Earp, Madalene A. , Goodman, Marc T. , Levine, Douglas A. , Menon, Usha , Ness, Roberta B., Pearce, Celeste Leigh, Rossing, Mary Anne, Wentzensen, Nicolas , Bean, Yukie T., Bisogna, Maria, Brinton, Louise A. , Carney, Michael E. , Cunningham, Julie M. , DeFazio, Anna , Dicks, Ed , Edwards, Robert P., Gayther, Simon A. , Gore, Martin, Iversen, Edwin S., Jensen, Allan , Johnatty, Sharon E., Lester, Jenny, Lin, Hui‐Yi , Lissowska, Jolanta , Lubiński, Jan , Menkiszak, Janusz , Moysich, Kirsten B. , Pike, Malcolm C. , Ramus, Susan J. , Song, Honglin , Terry, Kathryn L. , Thompson, Pamela J., Berg, David J. van den , Vierkant, Robert A. , Vitonis, Allison F., Walsh, Christine M. , Wu, Anna H. , Group, Georgia Chenevix-Trench on behalf of Australian Ovarian Cancer Study, Schildkraut, Joellen M. , Permuth‐Wey, Jennifer, Phelan, Catherine M., Sellers, Thomas A. , Goode, Ellen L. , Webb, Penelope M. , Whiteman, David C. , Chenevix‐Trench, Georgia , Bowtell, David D.L. , Ewing, Ailith , Fazio, Anna de , Larson, Melissa C. , Anton‐Culver, Hoda , Bandera, Elisa V. , Cramer, Daniel W. , Doherty, Jennifer A. , Gronwald, Jacek , Karlan, Beth Y. , Kjær, Susanne K. , Pejovic, Tanja B. , Cybulski, Cezary , Gentry‐Maharaj, Aleksandra , Modugno, Francesmary , Orlow, Irene , Tyrer, Jonathan P. , Wilkens, Lynne R. , Yang, Hannah , Ziogas, Argyrios , Berchuck, Andrew , Group, Georgia Chenevix-Trench on behalf of Australian Ovarian Cancer Study, Pharoah, Paul D.P. , Fridley, Brooke L. , Winham, Stacey J , Ramus, Susan J , Webb, Penelope M , Jensen, Allan , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Lissowska, Jolanta , Menkiszak, Janusz , Lin, Hui-Yi , Fogarty, Zachary C , Ewing, Ailith , Chenevix-Trench, Georgia , Whiteman, David C , Bowtell, David D , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | January 8, 2016 | Volume: 25 | Issue: 3 | Pages: 446-454

10.1158/1055-9965.epi-15-0240 | PMID 26747452 Get It

Abstract Background: While numerous susceptibility loci for epithelial ovarian cancer (EOC) have been identified, few associations have been reported with overall survival. In the absence of common prognostic genetic markers, we hypothesize that rare coding variants may be associated with overall EOC survival and assessed their contribution in two exome-based genotyping projects of the Ovarian Cancer Association Consortium (OCAC). Methods: The primary patient set (Set 1) included 14 independent EOC studies (4,293 patients) and 227,892 variants, and a secondary patient set (Set 2) included six additional EOC studies (1,744 patients) and 114,620 variants. Because power to detect rare variants individually is reduced, gene-level tests were conducted. Sets were analyzed separately at individual variants and by gene, and then combined with meta-analyses (73,203 variants and 13,163 genes overlapped). Results: No individual variant reached genome-wide statistical significance. A SNP previously implicated to be associated with EOC risk and, to a lesser extent, survival, rs8170, showed the strongest evidence of association with survival and similar effect size estimates across sets (Pmeta = 1.1E−6, HRSet1 = 1.17, HRSet2 = 1.14). Rare variants in ATG2B, an autophagy gene important for apoptosis, were significantly associated with survival after multiple testing correction (Pmeta = 1.1E−6; Pcorrected = 0.01). Conclusions: Common variant rs8170 and rare variants in ATG2B may be associated with EOC overall survival, although further study is needed. Impact: This study represents the first exome-wide association study of EOC survival to include rare variant analyses, and suggests that complementary single variant and gene-level analyses in large studies are needed to identify rare variants that warrant follow-up study. Cancer Epidemiol Biomarkers Prev; 25(3); 446–54. ©2016 AACR.
Applying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, Thomas, Gimona, Mario , Aigner, Ludwig , Börger, Verena , Buzás, Edit I. , Camussi, Giovanni , Chaput, Nathalie , Chatterjee, Devasis, Court, Felipe A. , Portillo, Hernando A. del , Fais, Stefano , Felderhoff‐Mueser, Ursula, Fraile, Lorenzo , Gho, Yong Song , Görgens, André , Gupta, Ramesh C. , Hendrix, An , Hill, Andrew F. , Hochberg, Fred H. , Horn, Peter A. , Kramer, Boris W. , Krämer‐Albers, Eva‐Maria , Laner‐Plamberger, Sandra , Laitinen, Saara , Leonardi, Tommaso , Lorenowicz, Magdalena J. , Lim, Sai Kiang , Lötvall, Jan , Maguire, Casey A. , Marcilla, Antonio , Nazarenko, Irina , Ochiya, Takahiro , Pedersen, Shona , Pòcsfalvi, Gabriella , Quesenberry, Peter J. , Reischl, Ilona , Rivera, Francisco J. , Sanzenbacher, Ralf, Schallmoser, Katharina , Slaper‐Cortenbach, Ineke , Strunk, Dirk , Vader, Pieter , Balkom, Bas W. M. van , Wauben, Marca H. M. , Andaloussi, Samir EL , Théry, Clotilde , Rohde, Eva , Giebel, Bernd , O’Driscoll, Lorraine , Falcón‐Pérez, Juan Manuel , Hermann, Dirk Matthias , Kleijn, Dominique P.V. de , Kordelas, Lambros , Patel, Tushar , Pluchino, Stefano , Tonn, Torsten , Leonardi, Tommaso , Nazarenko, Irina , Hill, Andrew F , Buzas, Edit I , Giebel, Bernd

Mayo Clinic

Journal of Extracellular Vesicles | December 31, 2015 | Volume: 4 | Issue: 1 | Pages: No page available

10.3402/jev.v4.30087 | PMID 26725829 Get It

Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell‐derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti‐tumour therapy, (b) pathogen vaccination, (c) immune‐modulatory and regenerative therapies and (d) drug delivery. The translation of EVs into clinical therapies requires the categorization of EV‐based therapeutics in compliance with existing regulatory frameworks. As the classification defines subsequent requirements for manufacturing, quality control and clinical investigation, it is of major importance to define whether EVs are considered the active drug components or primarily serve as drug delivery vehicles. For an effective and particularly safe translation of EV‐based therapies into clinical practice, a high level of cooperation between researchers, clinicians and competent authorities is essential. In this position statement, basic and clinical scientists, as members of the International Society for Extracellular Vesicles (ISEV) and of the European Cooperation in Science and Technology (COST) program of the European Union, namely European Network on Microvesicles and Exosomes in Health and Disease (ME‐HaD), summarize recent developments and the current knowledge of EV‐based therapies. Aspects of safety and regulatory requirements that must be considered for pharmaceutical manufacturing and clinical application are highlighted. Production and quality control processes are discussed. Strategies to promote the therapeutic application of EVs in future clinical studies are addressed.
Internal Fixation of Unstable Osteochondritis Dissecans in the Skeletally Mature Knee with Metal Screws
Barrett, Ian J. , King, Alexander H. , Riester, Scott M. , Wijnen, André J. van , Levy, Bruce A. , Krych, Aaron J. , Barrett, Ian, Riester, Scott, van Wijnen, Andre, Stuart, Michael J. , van Wijnen, Andre J , Krych, Aaron J

Mayo Clinic

CARTILAGE | December 30, 2015 | Volume: 7 | Issue: 2 | Pages: 157-162

10.1177/1947603515622662 | PMID 27047638 Get It

Purpose Several bioabsorbable and metal options are available for internal fixation of an unstable osteochondritis dissecans (OCD) lesion, but currently there are little data on outcomes with metal headless compression screws in the adult knee. The purpose of this study was to determine (1) the radiographic healing rates, (2) midterm clinical outcomes, and (3) comparison between healed and unhealed OCD fragments after use of headless metal compression screws for the treatment of unstable OCD lesions in the knees of skeletally mature patients. Methods Retrospective chart review for all skeletally mature patients who presented with unstable femoral condyle OCD lesions of the knee was conducted. All patients underwent open or arthroscopic reduction and internal fixation using headless metal compression screws. Preoperative and postoperative radiographs were reviewed with healing defined as radiographic evidence of union of the OCD progeny fragment with the condyle. Clinical outcome data were collected retrospectively using 3 validated outcome scores: International Knee Documentation Committee (IKDC), Knee Injury and Osteoarthritis Outcome Score (KOOS), and Marx. Results Twenty-two knees in 22 patients with a mean age of 21 years (range= 14-37 years) were followed for an average of 8.7 years (range = 2-22 years). Metal, headless, cannulated compression screws were used in all 22 cases. At a mean of 31 months postoperatively (range = 2-262), fragment union was observed in 18 knees (82%). The remaining 4 knees (18%) required loose fragment excision and hardware removal at a mean of 9 months (range = 2-16 months) postoperatively. Mean postoperative Marx score was 7 (range = 0-16), the mean postoperative IKDC score was 85 (range = 62-100), and mean KOOS scores included KOOS Pain (93; range = 69-100), KOOS Symptoms (86; range = 71-100), KOOS ADL (98; range = 90-100), KOOS Sports (82; range = 50-100), and KOOS QOL (76; range = 50-100). Conclusion Headless metal compression screws provide a satisfactory union rate for treatment of unstable OCD lesions of the femoral condyles in skeletally mature patients. Patients achieving union have good knee function, maintain satisfactory activity levels, and have superior knee outcomes compared with those that failed to heal after fixation at mid to long-term follow-up.
Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry–Based Assays
Hoofnagle, Andrew N. , Carr, Steven A. , Liu, Tao , Massoni, Sam A., Thomas, Stefani N. , Townsend, R. Reid , Zimmerman, Lisa J. , Boja, Emily S. , Chen, Jing , Crimmins, Daniel L., Davies, Sherri R. , Hiltke, Tara , Ketchum, Karen A. , Kinsinger, Christopher R. , Mesri, Mehdi , Meyer, Matthew R. , Qian, Weijun , Schoenherr, Regine M., Scott, Mitchell G., Shi, Tujin , Whiteley, Gordon , Wrobel, John A. , Wu, Chaochao, Ackermann, Brad, Barnidge, David R. , Bunk, David M. , Clarke, Nigel J. , Fishman, Jordan B., Grant, Russ P., Kushnir, Mark M. , Lowenthal, Mark S. , Neubert, Hendrik , Patterson, Scott D. , Rockwood, Alan L. , Rogers, John , Eyk, Jennifer E. Van , Wong, Steven, Zhang, Shucha, Chan, Daniel W. , Chen, Xian , Liebler, D.C. , Rodland, Karin , Rodriguez, Henry , Paulovich, Amanda G. , Whiteaker, Jeffrey R. , Kuhn, Eric W. , Gao, Yuqian , Aebersold, Ruedi , Grant, Russell P. , Kusebauch, Ulrike , Moritz, Robert L. , Singh, Ravinder J. , Ellis, Matthew J. , Smith, Richard , Zhang, Zhen , Zhang, Hui , Davies, S. J.

Mayo Clinic

Clinical Chemistry | December 30, 2015 | Volume: 62 | Issue: 1 | Pages: 48-69

10.1373/clinchem.2015.250563 | PMID 26719571 Get It

AbstractBACKGROUNDFor many years, basic and clinical researchers have taken advantage of the analytical sensitivity and specificity afforded by mass spectrometry in the measurement of proteins. Clinical laboratories are now beginning to deploy these work flows as well. For assays that use proteolysis to generate peptides for protein quantification and characterization, synthetic stable isotope–labeled internal standard peptides are of central importance. No general recommendations are currently available surrounding the use of peptides in protein mass spectrometric assays.CONTENTThe Clinical Proteomic Tumor Analysis Consortium of the National Cancer Institute has collaborated with clinical laboratorians, peptide manufacturers, metrologists, representatives of the pharmaceutical industry, and other professionals to develop a consensus set of recommendations for peptide procurement, characterization, storage, and handling, as well as approaches to the interpretation of the data generated by mass spectrometric protein assays. Additionally, the importance of carefully characterized reference materials—in particular, peptide standards for the improved concordance of amino acid analysis methods across the industry—is highlighted. The alignment of practices around the use of peptides and the transparency of sample preparation protocols should allow for the harmonization of peptide and protein quantification in research and clinical care.
Comprehensively understanding fatigue in patients with myeloproliferative neoplasms
Scherber, Robyn M. , Senyak, Zhenya, Dueck, Amylou C. , Clark, Matthew M. , Boxer, Michael , Geyer, Holly L. , McCallister, Archie, Cotter, Mary, Husen, Barbara Van, Harrison, Claire , Dueck, A. C. , Kosiorek, Heidi , Mesa, Ruben A.

Mayo Clinic

Cancer | December 15, 2015 | Volume: 122 | Issue: 3 | Pages: 477-485

10.1002/cncr.29753 | PMID 26670597 Get It

BACKGROUND Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs. METHODS A 70‐item, Internet‐based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center. RESULTS Fatigue was found to be prevalent and severe among international survey respondents (1788 respondents). Higher body mass index ( P <.001), current use of alcohol ( P <.001), and current tobacco use ( P = .0025) were found to be significantly associated with greater fatigue. Moderate/severe fatigue was present more frequently in those individuals who did not exercise compared with those who reported exercising at least once per week ( P <.001). Medical comorbidities found to be significantly associated with greater fatigue included restless leg syndrome ( P = .006), diabetes mellitus ( P = .045), fibromyalgia ( P < 0.001), chronic fatigue syndrome ( P = .006), and chronic kidney disease ( P = .02). Current use of antidepressants ( P <.001), antihistamines ( P = .0276), antianxiety medications ( P = .0357), and prescription pain medications ( P <.001) were found to be associated with worsened fatigue. Nearly 25% of respondents scored > 2 on the Patient Health Questionnaire, indicating a high probability of depression. Higher Brief Fatigue Inventory score, Myeloproliferative Neoplasm Total Symptom Score, and individual symptom items were all associated with a higher likelihood of depressive symptoms ( P <.0001). CONCLUSIONS The management of fatigue should be multifactorial, with a comprehensive assessment and treatment plan to address all modifiable fatigue etiologies. Patients with MPNs likely have a higher prevalence of mood disturbances compared with the general population, suggesting the need to assess and intervene in this domain. Cancer 2016;122:477–485. © 2015 American Cancer Society .
P4‐233: Small rnas in cerebrospinal fluid samples from patients with Alzheimer's disease and neurologically normal controls
Burgos, Kasandra, Beach, Thomas G. , Shill, Holly A. , Allen, Sean D. , Craig, David W. , Keuren‐Jensen, Kendall Van , Malenica, Ivana , Adler, Charles H.

Mayo Clinic

Alzheimer's & Dementia | December 15, 2015 | Volume: 11 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2015.08.062 Get It